MX2017005281A - Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa. - Google Patents
Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa.Info
- Publication number
- MX2017005281A MX2017005281A MX2017005281A MX2017005281A MX2017005281A MX 2017005281 A MX2017005281 A MX 2017005281A MX 2017005281 A MX2017005281 A MX 2017005281A MX 2017005281 A MX2017005281 A MX 2017005281A MX 2017005281 A MX2017005281 A MX 2017005281A
- Authority
- MX
- Mexico
- Prior art keywords
- boc
- piperidinyl
- ethyl
- kinase inhibitors
- janus kinase
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract 2
- BQXMJSXVUDFLCQ-UHFFFAOYSA-N N1(CCCCC1)C1=NC2=C(C=C1)N=NC2=O Chemical class N1(CCCCC1)C1=NC2=C(C=C1)N=NC2=O BQXMJSXVUDFLCQ-UHFFFAOYSA-N 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000042838 JAK family Human genes 0.000 abstract 3
- 108091082332 JAK family Proteins 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/089139 WO2016061751A1 (en) | 2014-10-22 | 2014-10-22 | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
| PCT/US2015/056541 WO2016064935A1 (en) | 2014-10-22 | 2015-10-21 | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017005281A true MX2017005281A (es) | 2017-08-15 |
Family
ID=55760043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005281A MX2017005281A (es) | 2014-10-22 | 2015-10-21 | Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10072025B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3209296B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017531672A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170068585A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107106547A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015336035A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017008103A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2964375A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017005281A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2017117248A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2016061751A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3452464B1 (en) | 2016-05-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Pyrazole derivatives, compositions and therapeutic use thereof |
| CN106749081B (zh) * | 2016-11-21 | 2019-06-25 | 浙江嘉圣生物医药有限公司 | 一种(s)-(4-溴-2-甲苯)(3-甲基吗啉)甲酮的制备方法 |
| WO2018118947A1 (en) | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| WO2018169777A1 (en) | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| SI3728215T1 (sl) | 2017-12-22 | 2022-01-31 | Siegfried Ag | Proces v enem loncu za pripravo racemnega nikotina z reagiranjem etil nikotinata z N-vinilpirolidonom v prisotnosti natrijevega etanolata ali kalijevega etanolata ali zmesi le-teh |
| WO2019214399A1 (zh) * | 2018-05-10 | 2019-11-14 | 罗欣药业(上海)有限公司 | 苯并七元杂环类化合物、其制备方法、药物组合物及应用 |
| EP3856737B1 (en) * | 2018-09-27 | 2023-05-17 | F. Hoffmann-La Roche AG | Heterocyclyl compounds for the treatment of autoimmune disease |
| CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
| US20230159520A1 (en) * | 2020-02-26 | 2023-05-25 | Beigene, Ltd. | Tyk-2 inhibitor |
| AU2021403827B2 (en) * | 2020-12-17 | 2024-07-25 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| CN114644633A (zh) * | 2020-12-18 | 2022-06-21 | 北京诺诚健华医药科技有限公司 | 杂环类jak抑制剂 |
| CN114939349B (zh) * | 2022-05-03 | 2023-08-01 | 北京工业大学 | 一种用于气体分离的金属-有机空穴配合物混合基质膜的制备 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| EP2976341B1 (en) | 2013-03-19 | 2018-02-28 | Merck Sharp & Dohme Corp. | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| EP2976338B1 (en) | 2013-03-19 | 2018-01-03 | Merck Sharp & Dohme Corp. | N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors |
| WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
-
2014
- 2014-10-22 WO PCT/CN2014/089139 patent/WO2016061751A1/en not_active Ceased
-
2015
- 2015-10-21 WO PCT/US2015/056541 patent/WO2016064935A1/en not_active Ceased
- 2015-10-21 KR KR1020177013258A patent/KR20170068585A/ko not_active Withdrawn
- 2015-10-21 EP EP15853280.4A patent/EP3209296B1/en active Active
- 2015-10-21 BR BR112017008103A patent/BR112017008103A2/pt not_active Application Discontinuation
- 2015-10-21 US US15/519,740 patent/US10072025B2/en active Active
- 2015-10-21 CN CN201580070401.7A patent/CN107106547A/zh active Pending
- 2015-10-21 AU AU2015336035A patent/AU2015336035A1/en not_active Abandoned
- 2015-10-21 JP JP2017521567A patent/JP2017531672A/ja not_active Withdrawn
- 2015-10-21 MX MX2017005281A patent/MX2017005281A/es unknown
- 2015-10-21 RU RU2017117248A patent/RU2017117248A/ru not_active Application Discontinuation
- 2015-10-21 CA CA2964375A patent/CA2964375A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015336035A1 (en) | 2017-04-20 |
| CA2964375A1 (en) | 2016-04-28 |
| KR20170068585A (ko) | 2017-06-19 |
| US10072025B2 (en) | 2018-09-11 |
| US20170240567A1 (en) | 2017-08-24 |
| CN107106547A (zh) | 2017-08-29 |
| EP3209296A1 (en) | 2017-08-30 |
| EP3209296A4 (en) | 2018-04-11 |
| WO2016061751A1 (en) | 2016-04-28 |
| JP2017531672A (ja) | 2017-10-26 |
| BR112017008103A2 (pt) | 2018-02-20 |
| EP3209296B1 (en) | 2019-07-10 |
| RU2017117248A (ru) | 2018-11-22 |
| WO2016064935A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017005281A (es) | Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa. | |
| ZA202401324B (en) | Tyrosine kinase inhibitors | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| WO2012054364A3 (en) | Bicyclic diamines as janus kinase inhibitors | |
| PH12017502050B1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| MY194262A (en) | Inhibitors of ret | |
| NZ729603A (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| EA033163B1 (ru) | Ингибиторы глутаминазы | |
| MX2015013419A (es) | Cianoetilpirazolo piridonas aciclicas como inhibidores de janus quinasa. | |
| WO2015200680A3 (en) | Prmt5 inhibitors and uses thereof | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| MX2013013090A (es) | Aminopirimidinas como inhibidores de tirosina cinaza del bazo. | |
| MX2015013418A (es) | Cicloalquil nitrilo pirazolo piridonas como inhibidores de janus quinasa. | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| NZ735631A (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| WO2016102672A3 (en) | Inhibitors of akt kinase | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX2020011472A (es) | Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide. | |
| MX2017015300A (es) | Derivados de aminoesteres. | |
| MX2016015959A (es) | Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3. |